Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05732883
Other study ID # KC/KE-22-0022/FR-4
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date January 1, 2024
Est. completion date March 2025

Study information

Verified date November 2023
Source Tseung Kwan O Hospital, Hong Kong
Contact Cherrie Ng
Phone +85235051409
Email cherrieng@ent.cuhk.edu.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Thyroidectomy is a standard procedure for benign and malignant pathologies of the thyroid gland. Each year, some 100 total thyroidectomies are performed in Kowloon East Cluster, Hospital Authority, Hong Kong. Total thyroidectomy is associated with voice dysfunction and temporary hypocalcaemia in up to 80% and 50%, respectively. Previous study from our institute showed a 3% rate of permanent vocal cord palsy and 16% of permanent hypoparathyroidism requiring calcium and/or vitamin D supplements. The use of dexamethasone has been studied in the past in total thyroidectomy patients and has been shown to be safe and effective in improving post-operative nausea and vomiting. No complications or drug related side effects were associated with a single dose of steroid. Recent studies have also shown that Dexamethasone is effective in improving voice outcome and hypocalcaemia in thyroidectomy patients. The investigators aim to study the effect of Dexamethasone in post-operative voice outcome and hypocalcaemia. Objective assessment of the vocal cords during phonation will be performed pre-operative and post-operatively. Serum Calcium level will be monitored.


Description:

This is a multi-specialty, double-blind, randomized, placebo-controlled trial involving the Departments of Surgery in United Christian Hospital, Tseung Kwan O Hospital and Department of Ear, Nose and Throat, United Christian Hospital and Tseung Kwan O Hospital, Kowloon East Cluster. The primary objective is to investigate the effect of Dexamethasone in post-operative voice outcome and hypocalcaemia in total thyroidectomy patients. The secondary outcome aims to investigate the mechanism of voice dysfunction in thyroidectomy patients using objective assessment tools. To streamline the practice among various departments and to minimize any potential confounders, the peri-operative anaesthetic and post-operative analgesic protocols are standardized. The surgical techniques are also standardized using capsular dissection with positive identification and preservation of the recurrent laryngeal nerve. Patient's voice and vocal cord mobility will be assessed pre-operatively and post-operatively. Objective assessment of the vocal cord will be carried out using video stroboscopy to document the mobility, waveform and vibration, symmetry and any arytenoid abnormality. Subjective and objective assessment of the voice outcome will be conducted by speech therapists using standardized voice assessment protocol. The trend of hypocalcaemia (Calcium level and parathyroid hormone level) will be monitored and correlated with the use of Dexamethasone. Possible side effect (e.g. wound infection) from the use of Dexamethasone will be analysed


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date March 2025
Est. primary completion date March 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Aged 18 or above - Patients undergoing total thyroidectomy for benign pathologies - MNG - Toxic nodular goitre - Graves' disease Exclusion Criteria: - Non-communicable patients - Patients contraindicated for steroid (DM, Hepatitis carrier, Tuberculosis, peptic ulcer disease) - Patients contraindicated for analgesics including Panadol, Celebrex, Tramadol or Levobupivacaine - Malignant thyroid disease - Patients with previous thyroid surgery, or neck surgery - Pre-existing hoarseness of voice of any cause or pre-existing vocal cord palsy - Pregnancy / Lactating female patients - Pre-existing renal disease / autoimmune disease on steroids - Patients who require steroid cover during operation e.g. hydrocortisone perioperatively

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dexamethasone
Dexamethasone injection
Normal saline
Placebo

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Tseung Kwan O Hospital, Hong Kong Chinese University of Hong Kong, United Christian Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Post-operative calcium and parathyroid hormone level on POD1 Serum calcium and parathyroid hormone level will be monitored Post-op 1 day
Primary Post-operative calcium and parathyroid hormone level after 3 months post-op Serum calcium and parathyroid hormone level will be monitored Post-op 3 months
Primary Post-operative calcium and parathyroid hormone level after 6 months post-op Serum calcium and parathyroid hormone level will be monitored Post-op 6 months
Primary Voice Handicap Index (VHI-10) Subjective voice assessment consisting of 10 questions. Each question 0-4 score Post-op 1 week
Primary Voice Handicap Index (VHI-10) Subjective voice assessment consisting of 10 questions. Each question 0-4 score Post-op 3 months
Primary Voice Handicap Index (VHI-10) Subjective voice assessment consisting of 10 questions. Each question 0-4 score Post-op 6 months
Primary Perceptual Evaluation: Cantonese Perceptual Evaluation of Voice (CanPEV) Objective voice assessment consisting of 10 questions. Each question 1-10 score. 1 being normal and 10 being the most severe voice dysfunction Post-op 1 week
Primary Perceptual Evaluation: Cantonese Perceptual Evaluation of Voice (CanPEV) Objective voice assessment consisting of 10 questions. Each question 1-10 score. 1 being normal and 10 being the most severe voice dysfunction Post-op 3 months
Primary Perceptual Evaluation: Cantonese Perceptual Evaluation of Voice (CanPEV) Objective voice assessment consisting of 10 questions. Each question 1-10 score. 1 being normal and 10 being the most severe voice dysfunction Post-op 6 months
Primary Acoustic Evaluation Instruct patient to sustain vowel /a/ and to read aloud the Hong Kong passage at a comfortable pitch and loudness level for about 3-5 seconds. Keep a distance of 15cm from the microphone for recording. Highlight the middle 3 seconds for analysis. To assess the fundamental frequency (Hz) and performance (dB) Post-op 1 week
Primary Acoustic Evaluation Instruct patient to sustain vowel /a/ and to read aloud the Hong Kong passage at a comfortable pitch and loudness level for about 3-5 seconds. Keep a distance of 15cm from the microphone for recording. Highlight the middle 3 seconds for analysis. To assess the fundamental frequency (Hz) and performance (dB) Post-op 3 months
Primary Acoustic Evaluation Instruct patient to sustain vowel /a/ and to read aloud the Hong Kong passage at a comfortable pitch and loudness level for about 3-5 seconds. Keep a distance of 15cm from the microphone for recording. Highlight the middle 3 seconds for analysis. To assess the fundamental frequency (Hz) and performance (dB) Post-op 6 months
Primary Aerodynamic Evaluation (Maximum sustained phonation) Instruct patient to sustain vowel /a/ at a comfortable pitch and loudness level for as long as possible after taking a deep breath. Recorded in seconds Post-op 1 week
Primary Aerodynamic Evaluation (Maximum sustained phonation) Instruct patient to sustain vowel /a/ at a comfortable pitch and loudness level for as long as possible after taking a deep breath. Recorded in seconds Post-op 3 months
Primary Aerodynamic Evaluation (Maximum sustained phonation) Instruct patient to sustain vowel /a/ at a comfortable pitch and loudness level for as long as possible after taking a deep breath. Recorded in seconds Post-op 6 months
Secondary Calcium and Rocaltrol requirement The required dosage of Calcium Carbonate and Rocaltrol will be documented Post-op 1 week
Secondary Calcium and Rocaltrol requirement The required dosage of Calcium Carbonate and Rocaltrol will be documented Post-op 3 months
Secondary Calcium and Rocaltrol requirement The required dosage of Calcium Carbonate and Rocaltrol will be documented Post-op 6 months
Secondary Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 Number of participants experiencing side effects from Dexamethasone will be documented Post-op 1 week
Secondary Stroboscopic Assessment (Vocal Fold Edge) Score 1-5 (1 - Smooth and straight; 5 - Rough and irregular) Post-op 1 week
Secondary Stroboscopic Assessment (Vocal Fold Edge) Score 1-5 (1 - Smooth and straight; 5 - Rough and irregular) Post-op 3 months
Secondary Stroboscopic Assessment (Vocal Fold Edge) Score 1-5 (1 - Smooth and straight; 5 - Rough and irregular) Post-op 6 months
Secondary Stroboscopic Assessment (Glottic Closure) Grading 1-7 (1. Complete 2. Anterior chink 3. Irregular 4. Bowing 5.Posterior chink 6. Hourglass 7 Incomplete) Post-op 1 week
Secondary Stroboscopic Assessment (Glottic Closure) Grading 1-7 (1. Complete 2. Anterior chink 3. Irregular 4. Bowing 5.Posterior chink 6. Hourglass 7 Incomplete) Post-op 3 months
Secondary Stroboscopic Assessment (Glottic Closure) Grading 1-7 (1. Complete 2. Anterior chink 3. Irregular 4. Bowing 5.Posterior chink 6. Hourglass 7 Incomplete) Post-op 6 months
Secondary Stroboscopic Assessment (Vertical Level of Approximation) 1 - Equal 2 - Right lower 3 - Left lower 4 - Questionable Post-op 1 week
Secondary Stroboscopic Assessment (Vertical Level of Approximation) 1 - Equal 2 - Right lower 3 - Left lower 4 - Questionable Post-op 3 months
Secondary Stroboscopic Assessment (Vertical Level of Approximation) 1 - Equal 2 - Right lower 3 - Left lower 4 - Questionable Post-op 6 months
Secondary Stroboscopic Assessment (Amplitude) 1 - Normal 2 - Slightly decreased 3 - Moderately decreased 4 - Severely decreased 5 - No visible movement Post-op 1 week
Secondary Stroboscopic Assessment (Amplitude) 1 - Normal 2 - Slightly decreased 3 - Moderately decreased 4 - Severely decreased 5 - No visible movement Post-op 3 months
Secondary Stroboscopic Assessment (Amplitude) 1 - Normal 2 - Slightly decreased 3 - Moderately decreased 4 - Severely decreased 5 - No visible movement Post-op 6 months
Secondary Stroboscopic Assessment (Mucosal wave) 1 - Normal 2 - Slightly decreased 3 - Moderately decreased 4 - Severely decreased 5 - Absent Post-op 1 week
Secondary Stroboscopic Assessment (Mucosal wave) 1 - Normal 2 - Slightly decreased 3 - Moderately decreased 4 - Severely decreased 5 - Absent Post-op 3 months
Secondary Stroboscopic Assessment (Mucosal wave) 1 - Normal 2 - Slightly decreased 3 - Moderately decreased 4 - Severely decreased 5 - Absent Post-op 6 months
Secondary Stroboscopic Assessment (Regularity) 1 - Regular 2 - Sometimes irregular 3 - Most irregular 4 - Always irregular Post-op 1 week
Secondary Stroboscopic Assessment (Regularity) 1 - Regular 2 - Sometimes irregular 3 - Most irregular 4 - Always irregular Post-op 3 months
Secondary Stroboscopic Assessment (Regularity) 1 - Regular 2 - Sometimes irregular 3 - Most irregular 4 - Always irregular Post-op 6 months
Secondary Stroboscopic Assessment (Ventricular folds) Movement - 1.Normal 2.Slight compress 3.Moderate compress 4.Full compress Post-op 1 week
Secondary Stroboscopic Assessment (Ventricular folds) Movement - 1.Normal 2.Slight compress 3.Moderate compress 4.Full compress Post-op 3 months
Secondary Stroboscopic Assessment (Ventricular folds) Movement - 1.Normal 2.Slight compress 3.Moderate compress 4.Full compress Post-op 6 months
See also
  Status Clinical Trial Phase
Completed NCT02892253 - Parathyroid Autofluorescence Visualization in Thyroid Surgery: Impact on Postoperative Hypocalcemia N/A
Completed NCT05043584 - Near-infrared Autofluorescence (NIRAF)-Guided Total Thyroidectomy: Impact in Low-volume, Non-parathyroid Institutions N/A
Recruiting NCT05885256 - Clinical Assessment of Low Calcium In traUMa (CALCIUM)
Recruiting NCT04160637 - Is There Benefit From Early Postoperative PTH Monitoring?
Completed NCT00506103 - The No-Tie Technique Using the Harmonic Scalpel in Total Thyroidectomy With Central Neck Dissection: A Prospective Randomized Study N/A
Recruiting NCT05585593 - Registry for Hypoparathyroidism Wuerzburg
Recruiting NCT04012476 - Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy Phase 4
Recruiting NCT05586529 - Effect of Preoperative High-dose Cholecalciferol in Prevention of Post-thyroidectomy Hypocalcaemia N/A
Completed NCT01868750 - Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia Phase 2
Completed NCT00668200 - Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast® Phase 4
Terminated NCT00623974 - Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia Phase 2
Completed NCT00630214 - Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection Phase 2
Not yet recruiting NCT03685877 - Hypocalcemia in Infants and Children
Terminated NCT00001151 - Studies With 1,25-Dihydroxycholecalciferol Phase 2
Completed NCT04750460 - Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). Phase 3
Not yet recruiting NCT03063060 - The Impact of Vitamin D Deficiency on Hypocalcaemia Following Total Thyroidectomy N/A
Not yet recruiting NCT04304573 - Is Correcting Total Serum Calcium Levels Important After Thyroidectomy
Recruiting NCT05216419 - Prevention of Postoperative Hypocalcemia of Oral Vitamin D Supplementation Before Total Thyroidectomy Phase 4
Recruiting NCT04775381 - Total Post-thyroidectomy Hypocalcemia After Preoperative Cholecalciferol Supplementation Phase 3
Active, not recruiting NCT01632514 - Vitamin D Deficiency and Postoperative Hypocalcemia Phase 4